Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma

NCT07584733 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Upper Tract Urothelial Carcinoma

Interventions

DRUG: RC48 Combined With Tislelizumab

Sponsor

RenJi Hospital

Collaborators

[object Object]
[object Object]
[object Object]